IP Library › Granted Patent US 12,310,974
Granted Patent B1
US 12,310,974 · App. 18/986,415 · Granted May 27, 2025

Method of treating post-traumatic stress disorder with carpipramine

Inventors: Samuel Aballea (Rotterdam, NL); Mondher Toumi (Luxembourg, LU)
A61K31/55A61P25/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,310,974
App. No.
18/986,415
Granted
May 27, 2025
Kind
B1
Abstract

A method of treating Post-Traumatic Stress Disorder in a subject comprising administering a therapeutically effective amount of carpipramine or a pharmaceutically acceptable salt thereof.

Claims (11)

1. A method of treating post-traumatic stress disorder (PTSD) in a subject, wherein the method comprises administering to the subject in need of treatment a therapeutically effective amount of carpipramine or a pharmaceutically acceptable salt thereof, where the carpipramine or its corresponding salt is the sole active ingredient.

2. The method according to claim 1 , wherein the administration is oral.

3. The method according to claim 1 , wherein the administration is intravenous.

4. The method according to claim 1 , wherein the administration is intramuscular.

5. The method according to claim 1 , wherein the amount administered is 50 to 400 mg per day.

6. The method according to claim 1 , wherein the treatment is administered daily.

7. The method according to claim 1 , wherein the treatment is administered in an extended-release formulation, lasting over several days, weeks or months.

8. The method according to claim 1 , wherein the subject was never previously treated with an antidepressant or antipsychotic.

9. The method according to claim 1 , wherein the subject previously failed to respond to treatment with an antidepressant selected from the group consisting of sertraline, paroxetine and venlafaxine.

10. The method according to claim 1 wherein the subject previously failed to respond to treatment with an antipsychotic selected from the group consisting of olanzapine, quetiapine, and aripiprazole.

11. The method according to claim 1 wherein the subject previously failed to respond to treatment with an antidepressant selected from the group consisting of sertraline, paroxetine and venlafaxine, and an antipsychotic selected from the group consisting of olanzapine, quetiapine, and aripiprazole administered sequentially or concomitantly.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2025
From: ABALLEA, SAMUEL; TOUMI, MONDHER
To: AVICENNE INVEST, S.A.
Reel/Frame 069842/0181 →
Continuity (1)
Provisional Application 63611902 · Dec 19, 2023
References Cited (17)
US 4956362A · Goni et al. · 1990 [cited by applicant]
US 5192799A · Tomino et al. · 1993 [cited by applicant]
US 5656299A · Kino et al. · 1997 [cited by applicant]
US 11123311B2 · Hammock et al. · 2021 [cited by applicant]
US 11298363B2 · Baska et al. · 2022 [cited by applicant]
US 11427604B2 · Slassi et al. · 2022 [cited by applicant]
US 11435689B2 · Kawakami et al. · 2022 [cited by applicant]
US 11591353B2 · Slassi et al. · 2023 [cited by applicant]
US 11597738B2 · Slassi et al. · 2023 [cited by applicant]
US 20060193788A1 · Hale et al. · 2006 [cited by applicant]
US 20090318398A1 · Dudley et al. · 2009 [cited by applicant]
US 20110172188A1 · Mouthon et al. · 2011 [cited by applicant]
US 20150272946A1 · Sato et al. · 2015 [cited by applicant]
US 20160060702A1 · Li et al. · 2016 [cited by applicant]
US 20190008850A1 · Markovitz · 2019 [cited by applicant]
US 20190125696A1 · Hammock et al. · 2019 [cited by applicant]
US 20210228570A1 · Renger · 2021 [cited by applicant]